Phase II Trial of BIBW 2992 in Patients With HER2-Positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy.

Trial Profile

Phase II Trial of BIBW 2992 in Patients With HER2-Positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2013

At a glance

  • Drugs Afatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2007-004805-80).
    • 20 Aug 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top